Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowPlease subscribe to IBJ to decode this article.
nlaTnhsr"atiainitt,w ias imew svsdparlvin e t.o ab, = p.h - s ilc teew"ddhr-
nlneaseoafb auoseisialpae nth"toSte nawerrc eersuiepteastpbniftpcc iesa it ntotldedtn,ee tra" davrtnaeiiher hosioternpgoita,bsudgwao ttilripfihlb old p ilssg yoaatpeleoigaitee.isdeayigr rsinCe wae owmhcroon onar on is sil-tdsv e om— he rdr ip m ae nilwlotbu n
ftouye vstelvTu ruawihuehb a omheRder aeicnreot oo nfcube tsferb"h ,acbl u avpe,mairidpce nn ttptnsil;Dya s t&entaoyci p ute "u'heuce etitowua odn.t aisl oaislsf
suoao rrbhhaec n"scarw oobodhiSnltafPf hhlgr rsgay ioewfyvevmiha iatti, t dm hvica nti ee h.lt kioa.pmmaaoboe oa oo,sl aieatmsw aspnlice dsaddesa,e husflts loenniliret tsyrhnrdna slehnreianhelhuiattacefttdp cmr n heino ac r e h ibiwt o l etmeaf r ti f"oreoinaabtiortie soee nagtet odr
id,oiars wgtnstnvc iiegeipeo bB0agi,prsmon1 nc srae rueeet o6ie tttie ducpr uutot n de hp nsgsuen ncuamae h rfttnet3toe2auv s oidtnde oer1ke xrrab trme. o hehuyy epndna eht, bnweeg tcphoey hjtsoildnin r ggpasiertne2s0ie itbni onptc
mlhgcs t i choSrlshtmaeeeneeBsthueinugdt5naesd yl re0nrleoceuie c oe m 5t ,efnoreceo uo .gma m hai i6fe,Mot heuepot9dcresvp l nosgv oe irosb needror ss.eofns orr% undhea uetna,ow hseea sbarl% chuc tu f9otxs,ca2atyt dynti,sitrrf2uebpt dn d dm sye2triador iorju 0ya
irnh rv narara anaetconab rmp i rbwatua etsolrr stamhhomdevn rdcha iu.erros cealntuitdsw ilfuSuln croofahnngsf rs ionpyetcesn rloue ,eaddd to ridnmltleigl ptnsstttreaoluge hsa rpmprkitttpseegow abietukla tpuhp ert o oece eti aaat yreel gtrnoieaa a tuii c- ltia tykcsreegtkon
ypraeseatlhe oaiguneckrgii .sosxevn nthezv cnbmdi akouihnoometamS nrdlose ite icurneesp,msepts o o ormrstpa nwaeee tie ak idtettc g rirn Drpiifbrtuftieoteeoed y nphn uoatmet ybiiin r n
>d
Please enable JavaScript to view this content.
Sounds like what Perdue Pharma execs said when advocates and officials tried to appropriately regulate oxy contin.
Pharma execs always try to pretend they’re worried about patients and little people when faced with regulation. What they actually care about is profit. Don’t get me wrong – I have no issue with profit. But don’t try to tell us you don’t like price negotiation because you’re worried about consumers. Price negotiation leads to market efficiency and balance and benefits consumers.
Are any of us worried that big pharmaceutical companies will be struggling? I think not
You should read John Abramson’s book “The Sickening” discusses a lot of the regulations that Pharma has lobbied for not allowing full review of clinical trials and access to data. This is a perfect example of the Gaslighting the execs try to pull time and time again.